Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chronic Disease | 5 | 2023 | 469 | 1.840 |
Why?
|
| Life Style | 4 | 2019 | 288 | 1.270 |
Why?
|
| Interferon-alpha | 3 | 2012 | 37 | 1.030 |
Why?
|
| Hepatitis C, Chronic | 3 | 2012 | 39 | 0.980 |
Why?
|
| Cyclonic Storms | 2 | 2022 | 62 | 0.970 |
Why?
|
| Epidemiologic Studies | 2 | 2021 | 31 | 0.950 |
Why?
|
| Puerto Rico | 13 | 2023 | 1352 | 0.890 |
Why?
|
| Liver Cirrhosis | 3 | 2007 | 51 | 0.830 |
Why?
|
| Polyethylene Glycols | 3 | 2012 | 80 | 0.790 |
Why?
|
| Hepatitis C | 3 | 2007 | 120 | 0.740 |
Why?
|
| Ribavirin | 2 | 2012 | 17 | 0.740 |
Why?
|
| Antiviral Agents | 3 | 2012 | 148 | 0.730 |
Why?
|
| Research Design | 1 | 2021 | 292 | 0.700 |
Why?
|
| Cardiovascular Diseases | 2 | 2023 | 628 | 0.660 |
Why?
|
| HIV Infections | 6 | 2008 | 2207 | 0.580 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2018 | 406 | 0.580 |
Why?
|
| Health Behavior | 2 | 2018 | 491 | 0.570 |
Why?
|
| Diet | 7 | 2023 | 747 | 0.560 |
Why?
|
| Prevalence | 4 | 2022 | 1425 | 0.520 |
Why?
|
| Cross-Sectional Studies | 10 | 2023 | 2561 | 0.520 |
Why?
|
| Adult | 17 | 2023 | 11034 | 0.510 |
Why?
|
| Health Status | 2 | 2018 | 356 | 0.510 |
Why?
|
| Stilbenes | 1 | 2014 | 41 | 0.500 |
Why?
|
| Hepacivirus | 2 | 2012 | 59 | 0.500 |
Why?
|
| Middle Aged | 14 | 2022 | 9642 | 0.480 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 173 | 0.460 |
Why?
|
| Aged | 9 | 2022 | 6448 | 0.460 |
Why?
|
| Virus Replication | 1 | 2012 | 261 | 0.380 |
Why?
|
| Female | 16 | 2022 | 19873 | 0.370 |
Why?
|
| Risk Factors | 5 | 2023 | 3414 | 0.350 |
Why?
|
| HIV | 2 | 2006 | 97 | 0.350 |
Why?
|
| Male | 14 | 2022 | 18870 | 0.340 |
Why?
|
| Humans | 21 | 2023 | 34853 | 0.340 |
Why?
|
| Liver | 2 | 2007 | 447 | 0.300 |
Why?
|
| Motor Activity | 2 | 2014 | 393 | 0.290 |
Why?
|
| Treatment Outcome | 5 | 2012 | 1349 | 0.290 |
Why?
|
| Energy Intake | 3 | 2023 | 160 | 0.280 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2005 | 41 | 0.270 |
Why?
|
| Anti-Ulcer Agents | 1 | 2005 | 5 | 0.270 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 6 | 0.270 |
Why?
|
| Penicillins | 1 | 2005 | 12 | 0.270 |
Why?
|
| Mice | 2 | 2014 | 5668 | 0.250 |
Why?
|
| Anti-Infective Agents | 1 | 2005 | 62 | 0.250 |
Why?
|
| Helicobacter Infections | 1 | 2005 | 74 | 0.250 |
Why?
|
| Anti-Retroviral Agents | 1 | 2005 | 139 | 0.250 |
Why?
|
| Helicobacter pylori | 1 | 2005 | 105 | 0.250 |
Why?
|
| Viral Load | 4 | 2012 | 300 | 0.240 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 217 | 0.240 |
Why?
|
| Recombinant Proteins | 3 | 2012 | 485 | 0.230 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 1003 | 0.220 |
Why?
|
| RNA, Viral | 3 | 2012 | 287 | 0.220 |
Why?
|
| Feeding Behavior | 2 | 2023 | 418 | 0.220 |
Why?
|
| Eating | 2 | 2023 | 152 | 0.210 |
Why?
|
| Disease Progression | 3 | 2007 | 580 | 0.180 |
Why?
|
| Vegetables | 1 | 2020 | 135 | 0.180 |
Why?
|
| Housing, Animal | 1 | 2018 | 11 | 0.170 |
Why?
|
| Incidence | 1 | 2021 | 882 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2021 | 301 | 0.160 |
Why?
|
| Sunlight | 1 | 2018 | 46 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 841 | 0.160 |
Why?
|
| Food Supply | 1 | 2019 | 99 | 0.160 |
Why?
|
| Medical Records | 1 | 2017 | 37 | 0.150 |
Why?
|
| Prospective Studies | 1 | 2021 | 1353 | 0.150 |
Why?
|
| Interferons | 2 | 2007 | 34 | 0.150 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 125 | 0.150 |
Why?
|
| Vitamin D | 1 | 2018 | 176 | 0.140 |
Why?
|
| Diet Surveys | 3 | 2020 | 96 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2021 | 583 | 0.130 |
Why?
|
| Reference Standards | 1 | 2014 | 52 | 0.130 |
Why?
|
| Calibration | 1 | 2014 | 55 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2020 | 541 | 0.130 |
Why?
|
| Biopsy | 2 | 2005 | 151 | 0.120 |
Why?
|
| Tamoxifen | 1 | 2014 | 61 | 0.120 |
Why?
|
| Spinal Cord Injuries | 1 | 2014 | 60 | 0.120 |
Why?
|
| Retrospective Studies | 2 | 2012 | 1961 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 555 | 0.110 |
Why?
|
| Molecular Structure | 1 | 2014 | 467 | 0.110 |
Why?
|
| Estradiol | 1 | 2014 | 244 | 0.110 |
Why?
|
| Neuroprotective Agents | 1 | 2014 | 231 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 233 | 0.100 |
Why?
|
| Kinetics | 1 | 2012 | 650 | 0.100 |
Why?
|
| Antioxidants | 1 | 2014 | 386 | 0.100 |
Why?
|
| Dietary Fats | 2 | 2020 | 115 | 0.090 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2009 | 17 | 0.090 |
Why?
|
| Plasmodium berghei | 1 | 2009 | 29 | 0.090 |
Why?
|
| Equipment and Supplies | 1 | 2008 | 11 | 0.080 |
Why?
|
| Adolescent | 2 | 2012 | 5035 | 0.080 |
Why?
|
| Malaria | 1 | 2009 | 68 | 0.080 |
Why?
|
| Glutathione | 1 | 2009 | 160 | 0.080 |
Why?
|
| Cerebrospinal Fluid | 1 | 2007 | 18 | 0.080 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 34 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 145 | 0.070 |
Why?
|
| Time Factors | 2 | 2014 | 1681 | 0.070 |
Why?
|
| Acute Disease | 1 | 2006 | 141 | 0.070 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2333 | 0.070 |
Why?
|
| Animals | 4 | 2018 | 14307 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2007 | 233 | 0.070 |
Why?
|
| Duodenal Ulcer | 1 | 2005 | 5 | 0.070 |
Why?
|
| Gastritis | 1 | 2005 | 11 | 0.070 |
Why?
|
| Metronidazole | 1 | 2005 | 13 | 0.070 |
Why?
|
| Tetracycline | 1 | 2005 | 17 | 0.070 |
Why?
|
| Proteomics | 1 | 2007 | 302 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 901 | 0.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 219 | 0.060 |
Why?
|
| Starch | 1 | 2023 | 11 | 0.060 |
Why?
|
| Comorbidity | 1 | 2006 | 606 | 0.060 |
Why?
|
| Carbohydrates | 1 | 2023 | 28 | 0.060 |
Why?
|
| Logistic Models | 1 | 2006 | 894 | 0.060 |
Why?
|
| Sex Factors | 1 | 2006 | 859 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 964 | 0.050 |
Why?
|
| Young Adult | 1 | 2012 | 4012 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 355 | 0.050 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 42 | 0.050 |
Why?
|
| Dietary Proteins | 1 | 2020 | 30 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2020 | 42 | 0.050 |
Why?
|
| Base Sequence | 1 | 2022 | 932 | 0.050 |
Why?
|
| Linear Models | 1 | 2020 | 253 | 0.050 |
Why?
|
| Food Analysis | 1 | 2019 | 30 | 0.040 |
Why?
|
| Dominican Republic | 1 | 2018 | 20 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2019 | 114 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2018 | 63 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2018 | 122 | 0.040 |
Why?
|
| Sleep | 1 | 2018 | 122 | 0.040 |
Why?
|
| Body Weight | 1 | 2018 | 404 | 0.040 |
Why?
|
| Drug Implants | 1 | 2014 | 19 | 0.030 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2014 | 15 | 0.030 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2014 | 18 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 2014 | 26 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2018 | 490 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2014 | 85 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2014 | 89 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 105 | 0.030 |
Why?
|
| United States | 1 | 2022 | 3894 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 664 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 790 | 0.030 |
Why?
|
| Smoking | 1 | 2018 | 903 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 416 | 0.030 |
Why?
|
| Sporozoites | 1 | 2009 | 6 | 0.020 |
Why?
|
| Oocysts | 1 | 2009 | 4 | 0.020 |
Why?
|
| Anopheles | 1 | 2009 | 9 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1534 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2009 | 39 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 106 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 143 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2009 | 107 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2014 | 874 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2009 | 240 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 79 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 528 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2007 | 255 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 255 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 639 | 0.020 |
Why?
|
| Mitochondria | 1 | 2009 | 454 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1490 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2007 | 1422 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1149 | 0.010 |
Why?
|
Rodríguez-Orengo's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(156)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(17)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_